{"name":"Nuron Biotech Inc.","slug":"nuron-biotech-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"NU100","genericName":"NU100","slug":"nu100","indication":"Relapsing forms of multiple sclerosis","status":"phase_3"},{"name":"rhIFN beta-1b","genericName":"rhIFN beta-1b","slug":"rhifn-beta-1b","indication":"Relapsing forms of multiple sclerosis","status":"phase_3"}]}],"pipeline":[{"name":"NU100","genericName":"NU100","slug":"nu100","phase":"phase_3","mechanism":"NU100 is a small molecule that targets the S1P1 receptor.","indications":["Relapsing forms of multiple sclerosis"],"catalyst":""},{"name":"rhIFN beta-1b","genericName":"rhIFN beta-1b","slug":"rhifn-beta-1b","phase":"phase_3","mechanism":"rhIFN beta-1b is a recombinant form of interferon beta-1b that modulates the immune system to reduce inflammation in the central nervous system.","indications":["Relapsing forms of multiple sclerosis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxORkhDT1g0bmJlb0RaMnhib1hqcDJ0VDVoamNsdVhWZ0s2cXRzZHA1bVpmaGNjVnJFZUN1NXRhbExyOEJsQ3pvcnZJMUNXQXJHUHM2VE9CaUJ0LW8zZkNiLUpsb185eFdLaHdWbUE5UUkyOVBaUFd4WEk4QkU5WF9OM2VGbkVNVWNnV0s4ZmVmUFRxYVZqRXgzRmozb0N1YTlI?oc=5","date":"2017-06-15","type":"pipeline","source":"Fierce Biotech","summary":"Eye specialist Ocugen looks east for second-round fundraising - Fierce Biotech","headline":"Eye specialist Ocugen looks east for second-round fundraising","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPVWZidWw2ODZLcnBuV1JCOUNZYUhra3U1c2JmelIyMGwwV0k1ZWpWOW1UQjlxRk1zXy13blFxQVppT3JZVnpUVFlCdnZPM1NIYnRhU09PUkFrYkFxM0phcU5iYmJBVW11T0lwbXhYM3RfOGo1V3pVNVY4Wnc3TlRxcWtobw?oc=5","date":"2012-12-11","type":"pipeline","source":"Inquirer.com","summary":"Business news in brief - Inquirer.com","headline":"Business news in brief","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQS3Rsb09wU2Fyc1Q0VFFNRWFYVFJvTXMwdFN4X2VhZjNDaGw3RVRnNWVWdWE4UW9kaUFGYVdNdVRXZXo5WVR0Y2FDZ3NLcVVWSXpEMkhqV2JwQklMVHhQMVdHeldsSHl5Skp5aTd5QXg4M2hOdTYtUXFOaWF3dldXYzI2T3VWVzMzU2c?oc=5","date":"2012-03-14","type":"pipeline","source":"UConn Today","summary":"Pharmacy Alum Makes His Mark in Biotechnologies - UConn Today","headline":"Pharmacy Alum Makes His Mark in Biotechnologies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQdEpQNUFfY2g2VDhYWkVmUTJHMGg4QURjb0pBblRRa05WR2Nab1BBQWMtbElXdGt6ODV4NmNITVNzZ0dfYTROSzlNX2plcGZVUW5WWUZMOTlTTXBfOFJvSDVtc2JXeUpVZDg3R2NhQ0tYblBjSE4tS1k4NVVhbC1SSTFhMlE?oc=5","date":"2011-04-06","type":"deal","source":"Genetic Engineering and Biotechnology News","summary":"Nuron Acquires Hib Disease Vaccine from Wyeth - Genetic Engineering and Biotechnology News","headline":"Nuron Acquires Hib Disease Vaccine from Wyeth","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}